Cas:680618-02-4 5-[(4-cyanobenzoyl)amino]-2-ethoxybenzenesulfonyl chloride manufacturer & supplier

We serve Chemical Name:5-[(4-cyanobenzoyl)amino]-2-ethoxybenzenesulfonyl chloride CAS:680618-02-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-[(4-cyanobenzoyl)amino]-2-ethoxybenzenesulfonyl chloride

Chemical Name:5-[(4-cyanobenzoyl)amino]-2-ethoxybenzenesulfonyl chloride
CAS.NO:680618-02-4
Synonyms:AB1356;5-(4-Cyanobenzamido)-2-ethoxybenzene-1-sulfonyl chloride;5-(4-CYANO-BENZOYLAMINO)-2-ETHOXY-BENZENESULFONYL CHLORIDE
Molecular Formula:C16H13ClN2O4S
Molecular Weight:364.80300
HS Code:2926909090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:104.64000
Exact Mass:364.02800
LogP:4.29058

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like AB1356 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(4-CYANO-BENZOYLAMINO)-2-ETHOXY-BENZENESULFONYL CHLORIDE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(4-Cyanobenzamido)-2-ethoxybenzene-1-sulfonyl chloride Use and application,AB1356 technical grade,usp/ep/jp grade.


Related News: “The most important thing to be considered while determining a CDMO competency is their technical knowledge along with adequate expertise to accomplish the drug development till commercial scaling. N-Phenylaniline sulfate (1:1) manufacturers The review considered two cases of AML in patients treated with an investigational medicine, bb1111, in a clinical trial for sickle cell disease. Although there have been no reports of AML with Zynteglo, both medicines use the same viral vector and there was a concern that the vector may be implicated in the development of the cancer (insertional oncogenesis). Astaxanthin suppliers Results from a Phase I clinical trial, published in The Lancet, found that two-doses of the inhaled Ad5-nCoV vaccine can trigger a similar immune response to a single-dose of the injected version. n-tetradecyl-beta-d-maltoside vendor & factory.